SMA-560 Orthotopic Mouse Model Service for Brain Cancer

The SMA-560 orthotopic mouse model for brain cancer provides a spontaneously arising, immunocompetent astrocytoma platform that faithfully recapitulates the TGF-β-driven immunosuppression, low basal MHC class I expression, and invasive growth dynamics characteristic of human glioblastoma. Alfa Cytology delivers this specialized orthotopic model service with integrated capabilities spanning stereotactic surgical implantation into VM/Dk hosts, longitudinal bioluminescence and MRI monitoring, immune microenvironment profiling, and comprehensive endpoint analysis—empowering researchers to dissect glioma immunobiology and accelerate preclinical therapeutic development with precision.

Overview of SMA-560 Orthotopic Mouse Model for Brain Cancer

The SMA-560 cell line traces its origin to a spontaneous astrocytoma that arose in an inbred VM/Dk mouse in 1971, as first described by Fraser, and was subsequently established as a stable tumorigenic line in 1980 through serial transplantation and in vitro adaptation by Serano and colleagues. Unlike carcinogen-induced glioma models, SMA-560 developed naturally within its syngeneic host, offering a biologically authentic representation of de novo gliomagenesis. Histologically, the tumors display high cellularity, hyperchromatic nuclei, occasional mitotic figures, and an invasive tumor border with focal areas of necrosis and vascular proliferation—features consistent with anaplastic astrocytoma. The cells exhibit strong glial fibrillary acidic protein (GFAP) and glutamine synthetase staining, confirming their astrocytic lineage, while showing minimal S100 expression. Genetically, SMA-560 carries a substantial mutational burden with approximately 2,171 non-synonymous exome mutations, and its gene expression profile reveals upregulation of immunoregulatory pathways, interferon-responsive genes, and antigen presentation machinery when grown in immunocompetent hosts.

Fig 1. Combined irradiation+TRAM-34 therapy increases survival in the SMA-560 VM/Dk glioma model. (Stransky, Nicolai, et al., 2023)

A defining characteristic of the SMA-560 model is its robust expression of transforming growth factor beta (TGF-β), a potent immunosuppressive cytokine centrally implicated in human glioblastoma pathogenesis through its roles in dampening cytotoxic T-cell proliferation, promoting regulatory T-cell recruitment, and driving angiogenesis. Additionally, tumor-infiltrating lymphocytes within SMA-560 gliomas display marked upregulation of exhaustion markers including PD-1, TIM-3, and LAG-3, with nearly half of CD8+ T cells co-expressing all three checkpoints—a pattern strikingly similar to human GBM. The model exhibits low baseline MHC class I and undetectable MHC class II expression, creating an immune-evasive landscape that makes it particularly valuable for evaluating TGF-β inhibitors, checkpoint blockade combinations, and strategies aimed at reversing glioma-induced immunosuppression. When orthotopically implanted into VM/Dk mice, SMA-560 forms aggressively infiltrative intracranial tumors with a median survival of approximately 26 days, providing a rigorous preclinical window for therapeutic intervention.

Cell Line Information: SMA-560

The table below provides comprehensive characterization data for the SMA-560 murine astrocytoma cell line to guide experimental design and model selection for brain cancer preclinical studies.

Our Services

Alfa Cytology provides a comprehensive SMA-560 orthotopic mouse model service tailored to the unique demands of glioma immunotherapy and TGF-β biology research, encompassing precision stereotactic implantation into VM/Dk hosts, longitudinal non-invasive imaging, immune microenvironment phenotyping, and detailed histopathological and molecular endpoint characterization. Our neuro-oncology team ensures reproducible tumor kinetics, stringent quality assurance, and adaptable study architectures that align seamlessly with your preclinical development objectives.

Workflow of SMA-560 Orthotopic Mouse Model Construction

Construction of the SMA-560 orthotopic glioma model employs a refined stereotactic neurosurgical protocol optimized for the VM/Dk host strain, ensuring high engraftment fidelity, minimal perioperative morbidity, and consistent intracranial tumor progression. The workflow integrates cell quality verification, precision intracranial delivery, and longitudinal multimodal monitoring to generate robust, publication-quality preclinical datasets.

1. Cell Line Authentication and Expansion: SMA-560 cells are authenticated by mouse STR profiling and expanded in MEM (Richter's modification) complete medium to ensure phenotypic stability, GFAP/glutamine synthetase marker integrity, and viability >95% prior to surgical preparation.
2. Host Selection and Acclimatization: Syngeneic VM/Dk mice—typically 6–10 weeks old and 20–22 g—are acclimatized for at least one week with health screening and baseline body weight recording; age-matched cohorts are employed given documented differences in tumorigenic potential between young and old VM/Dk mice.
3. Anesthesia and Surgical Preparation: Mice are anesthetized with isoflurane (induction 3%, maintenance 1.5–2%) delivered via nose cone on a stereotactic frame with a thermoregulated heating pad; the scalp is shaved, disinfected with alternating betadine and alcohol swabs, and the periosteum is exposed.
4. Stereotactic Coordinate Calibration: Bregma is identified after gentle periosteal reflection; a 0.9 mm burr hole is drilled at coordinates 2 mm lateral and 2 mm posterior to bregma, targeting the right striatum, with the dura mater left intact to minimize cortical trauma.
5. Intracranial Cell Injection: A Hamilton syringe loaded with 5 µL of SMA-560 cell suspension (1 × 10⁴ to 2.5 × 10⁴ viable cells in PBS or 2.5% methylcellulose) is inserted to a depth of 4 mm, withdrawn 1 mm to create a deposition pocket, and cells are slowly injected over 3–5 minutes; the needle is held in place for 1 minute to prevent reflux.
6. Cranial Closure and Postoperative Care: The burr hole is sealed with bone wax or sterile collagen sponge, the scalp incision is closed with surgical adhesive or sutures, and mice are recovered on a heated pad with buprenorphine analgesia per institutional animal care guidelines.
7. Tumor Establishment Verification: Tumor engraftment is confirmed 5–7 days post-implantation via bioluminescence imaging (for luciferase-transduced lines) or contrast-enhanced micro-MRI; mice displaying confirmed tumor signals are randomized into vehicle and treatment cohorts.
8. Longitudinal Monitoring and In-Life Assessment: Tumor burden is tracked weekly via bioluminescence imaging, T2-weighted MRI, or micro-CT; concurrent recording of body weight, neurological deficit scoring, and overall clinical condition enables early detection of treatment-related toxicities.
9. Treatment Administration: Investigational agents—including TGF-β inhibitors, checkpoint blockade antibodies, oncolytic viruses, targeted small molecules, or combination regimens—are administered according to protocol-defined schedules via intracranial, intravenous, intraperitoneal, or oral routes as appropriate.
10. Necropsy and Tissue Procurement: At study endpoint, brains are harvested en bloc, photographed, and sectioned coronally; tumor dimensions are measured, and tissue aliquots are allocated for formalin-fixed paraffin embedding, snap-freezing, and downstream molecular analysis.
11. Histopathological and Immune Phenotyping: Tumor sections undergo H&E staining, IHC for GFAP, Ki-67, CD31, TGF-β, phospho-SMAD2/3, and PD-L1, alongside flow cytometry of tumor-infiltrating lymphocytes (CD4+, CD8+, Treg, MDSC, macrophage subsets) to characterize immune modulation and pathway engagement.
12. Data Integration and Reporting: All imaging, survival, biometric, and molecular data are compiled into a comprehensive study report with Kaplan-Meier survival curves, tumor growth kinetics, immunophenotyping summaries, and pharmacodynamic interpretations suitable for regulatory or publication use.

Fig 2. SMA-560 Orthotopic Mouse Model construction workflow.

Case Study-SMA-560 Orthotopic Mouse Model Development

In a representative preclinical program, the SMA-560 orthotopic glioma model was established in VM/Dk mice with reproducible tumor take and aggressive intracranial growth dynamics yielding a median survival window of approximately 26 days. Treatment cohorts receiving a TGF-β receptor kinase inhibitor demonstrated modest survival prolongation relative to vehicle controls, accompanied by reduced intratumoral TGF-β signaling and decreased regulatory T-cell infiltration as assessed by flow cytometry and phospho-SMAD2/3 IHC. A combination arm pairing the TGF-β inhibitor with an anti-PD-1 antibody showed enhanced therapeutic synergy, with a subset of animals exhibiting durable tumor control beyond 40 days and improved CD8+ effector T-cell recruitment. Detailed quantitative datasets—including bioluminescence tumor growth curves, Kaplan-Meier survival metrics, neurological scoring trends, and immune profiling data—are available for review; please reach out to our scientific team to discuss how these findings can inform your specific glioma therapeutic strategy.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your SMA-560 orthotopic model program provides access to a specialized neuro-oncology service platform with deep expertise in spontaneous glioma biology, VM/Dk host management, and immunosuppressive microenvironment analysis.

• Established proficiency with the VM/Dk syngeneic host system and optimized stereotactic protocols that yield consistent SMA-560 engraftment and predictable survival kinetics.
• Unique capability to evaluate TGF-β-targeted interventions with integrated biomarker analysis, including phospho-SMAD profiling and Treg/MDSC quantification.
• In-house multimodal imaging infrastructure—bioluminescence, MRI, and micro-CT—for non-invasive longitudinal tumor monitoring and early pharmacodynamic readouts.
• Comprehensive immune exhaustion profiling spanning PD-1, TIM-3, and LAG-3 co-expression analysis on tumor-infiltrating CD8+ T cells to mirror human GBM immunophenotypes.
• Flexible study designs supporting monotherapy, combination, sequential, and age-stratified arms tailored to your compound mechanism and regulatory requirements.
• Rigorous cell authentication, health surveillance, and GLP-aligned documentation practices that uphold data integrity for IND-enabling and peer-review standards.

Contact Us

To explore how the SMA-560 orthotopic mouse model can advance your brain cancer preclinical program, we invite you to reach out to us for a confidential scientific consultation. Our neuro-oncology specialists will evaluate your therapeutic target, propose a customized study design leveraging the unique TGF-β immunosuppressive features of this spontaneous glioma model, and outline a clear roadmap to generating the high-quality data your discovery team requires. Contact us today and let Alfa Cytology drive your next preclinical milestone in glioblastoma research.

For research use only. Not intended for any clinical use.